surmount-1 tirzepatide surmount once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight – SURMOUNT-1

Key Indications Conditions such as depressive disorders, anxiety-related conditions, and neuropathic pain linked to diabetic peripheral neuropathy

Weight loss velocity peaked between weeks 12 and 24, with participants losing approximately 1.5 to 2 pounds weekly during this period

In this case, consider asking your doctor about Wegovy (semaglutide approved for weight loss), which some plans cover for obesity treatment, or explore cash-pay options

1517 The GLP-1R stimulation in smooth muscle cells leads to a decrease in both their proliferation and the migration of smooth muscle cells into a plaque

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study